The global hyperphosphatemia drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic kidney disease and other conditions that lead to hyperphosphatemia, such as cancer and diabetes. The increase in the number of patients with chronic kidney disease will drive the demand for phosphate binders in hospitals and clinics. Aluminum Phosphate Binder: Aluminum phosphate binders are used for treating hyperphosphatemia by binding phosphorus in the gastrointestinal tract, thereby preventing its absorption into the bloodstream. This type of binder is available as aluminum hydroxide or aluminum carbonate gel capsules or tablets, which are taken orally with water before meals or after meals. Aluminum phosphate binders are used for treating hyperphosphatemia by binding phosphorus in the gastrointestinal tract, thereby preventing its absorption into the bloodstream. Iron Phosphate Binder: Iron phosphate binders are used for treating hyperphosphatemia by binding phosphorus in blood plasma and tissues through an iron-containing complex called ferric pyrophosphate (FPP). These types of binders can be administered intravenously (IV) through a needle inserted into a vein; intramuscularly (IM) through a needle inserted into muscle; subcutaneously (SC) under skin; intraperitoneally (IP) inside abdomen; rectally via suppository; vaginally via vaginal insert tablet/suppository/gel capsule/tablet/capsule; transdermally via patch applied on skin surface near stomach area; nasogastric tube inserted through nose down throat passage towards stomach area where it remains until removed from body naturally after some time period depending on dosage form selected by physician); oral route either as liquid suspension mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc; topical route either as cream applied on skin surface near stomach area where it remains until removed from body naturally after some time period depending on dosage form selected by physician); oral route either as liquid suspension mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc, chewable tablet mixed with food items like milk shake etc; topical route either as cream applied on skin surface near stomach area where it remains until removed from body naturally after some time period depending on dosage form selected by physician). Magnesium Phosphate Binder: Magnesium phosphate binds phosphates within cells and prevents their release back into circulation when they would otherwise be excreted out in urine due to renal failure caused due to various reasons including diabetes mellitus type 2, chronic kidney disease stage 3-5 CKD), congestive heart failure CHF), hypertension HTN), nephrotic syndrome NS), polycystic kidney PKD), primary renal tubular acidosis PRTA). It also helps maintain normal levels of magnesium within cells while reducing serum levels below normal range so that they do not interfere adversely affect cardiac function erythrocyte production erythropoiesis erythropoiesis).
Some Of The Growth Factors Of This Market:
- The increasing prevalence of chronic kidney disease and the associated hyperphosphatemia is a major factor driving the growth of the market.
- The increasing number of patients with end-stage renal disease is also a major factor driving the growth of this market.
- The increase in awareness about hyperphosphatemia and its treatment options among physicians is also a major factor driving this market's growth.
- Increasing incidence rates for chronic kidney disease, which leads to an increased prevalence of hyperphosphatemia, are also factors that are expected to drive this market's growth over the forecast period (2017-2026).
- Increasing geriatric population base in developed countries such as North America and Europe is another key driver for this market's growth over the forecast period (2017-2026).
Industry Growth Insights published a new data on “Hyperphosphatemia Drugs Market”. The research report is titled “Hyperphosphatemia Drugs Market research by Types (Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder), By Applications (Hospitals, Clinics, Others), By Players/Companies Keryx Biopharmaceuticals, Sanofi, Shire, Vifor Pharma, Amgen, Bayer”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hyperphosphatemia Drugs Market Research Report
By Type
Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder
By Application
Hospitals, Clinics, Others
By Companies
Keryx Biopharmaceuticals, Sanofi, Shire, Vifor Pharma, Amgen, Bayer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Hyperphosphatemia Drugs Market Report Segments:
The global Hyperphosphatemia Drugs market is segmented on the basis of:
Types
Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Keryx Biopharmaceuticals
- Sanofi
- Shire
- Vifor Pharma
- Amgen
- Bayer
Highlights of The Hyperphosphatemia Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Aluminum Phosphate Binder
- Iron Phosphate Binder
- Magnesium Phosphate Binder
- Calcium Phosphate Binder
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hyperphosphatemia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hyperphosphatemia drugs are medications that help to lower blood phosphate levels. This can help to prevent or treat a variety of health problems, including kidney stones and heart disease.
Some of the key players operating in the hyperphosphatemia drugs market are Keryx Biopharmaceuticals, Sanofi, Shire, Vifor Pharma, Amgen, Bayer.
The hyperphosphatemia drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hyperphosphatemia Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hyperphosphatemia Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hyperphosphatemia Drugs Market - Supply Chain
4.5. Global Hyperphosphatemia Drugs Market Forecast
4.5.1. Hyperphosphatemia Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hyperphosphatemia Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hyperphosphatemia Drugs Market Absolute $ Opportunity
5. Global Hyperphosphatemia Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
5.3.1. Aluminum Phosphate Binder
5.3.2. Iron Phosphate Binder
5.3.3. Magnesium Phosphate Binder
5.3.4. Calcium Phosphate Binder
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hyperphosphatemia Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hyperphosphatemia Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hyperphosphatemia Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hyperphosphatemia Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hyperphosphatemia Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hyperphosphatemia Drugs Demand Share Forecast, 2019-2026
9. North America Hyperphosphatemia Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
9.7.1. Aluminum Phosphate Binder
9.7.2. Iron Phosphate Binder
9.7.3. Magnesium Phosphate Binder
9.7.4. Calcium Phosphate Binder
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hyperphosphatemia Drugs Demand Share Forecast, 2019-2026
10. Latin America Hyperphosphatemia Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
10.7.1. Aluminum Phosphate Binder
10.7.2. Iron Phosphate Binder
10.7.3. Magnesium Phosphate Binder
10.7.4. Calcium Phosphate Binder
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hyperphosphatemia Drugs Demand Share Forecast, 2019-2026
11. Europe Hyperphosphatemia Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
11.7.1. Aluminum Phosphate Binder
11.7.2. Iron Phosphate Binder
11.7.3. Magnesium Phosphate Binder
11.7.4. Calciu Phosphate Binder
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hyperphosphatemia Drugs Demand Share, 2019-2026
12. Asia Pacific Hyperphosphatemia Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
12.7.1. Aluminum Phosphate Binder
12.7.2. Iron Phosphate Binder
12.7.3. Magnesium Phosphate Binder
12.7.4. Calcium Phosphate Binder
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hyperphosphatemia Drugs Demand Share, 2019-2026
13. Middle East & Africa Hyperphosphatemia Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hyperphosphatemia Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hyperphosphatemia Drugs Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hyperphosphatemia Drugs Market Size and Volume Forecast by Type
13.7.1. Aluminum Phosphate Binder
13.7.2. Iron Phosphate Binder
13.7.3. Magnesium Phosphate Binder
13.7.4. Calcium Phosphate Binder
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hyperphosphatemia Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hyperphosphatemia Drugs Market: Market Share Analysis
14.2. Hyperphosphatemia Drugs Distributors and Customers
14.3. Hyperphosphatemia Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Keryx Biopharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Shire
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Vifor Pharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Amgen
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bayer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook